Deals and Financings • MGI Tech a Shenzhen maker of gene sequencing machines and a subsidiary of genomics company BGI, completed an A funding of more than $200 million; • Xynomic Pharma closed its business combination with Bison Capital Acquisition, ...

 


 

ChinaBio® Weekly Update

Contents


Week in Review: MGI Tech Raises $200 Million to Manufacture Genomic Sequencing Machines

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Deals and Financings

• MGI Tech a Shenzhen maker of gene sequencing machines and a subsidiary of genomics company BGI, completed an A funding of more than $200 million;
• Xynomic Pharma closed its business combination with Bison Capital Acquisition, becoming a wholly-owned subsidiary of BCAC in a $191.6 million deal;
• HanX Biopharma, a China oncology company, in-licensed China rights to a Phase III candidate for myelodysplastic syndromes from Onconova in a $51.5 million agreement;
• AnHeart Therapeutics of Hangzhou raised $14.6 million to develop in-licensed oncology drugs in a Series A round from Decheng Capital;
• US-based Leads Biolabs, a fully-owned subsidiary of Nanjing Leads Biolabs, granted Pneuma a license to develop inhaled versions of Leads' immuno-oncology candidates;
• China's Winhealth Pharma in-licensed greater China rights for two FDA approved pain management drugs from Cumberland Pharma;
• Shenzhen Mindray signed an agreement allowing it to use Masimo's technology for noninvasive, continuous measurement of pulse oximetry;
• Shanghai ChemPartner, a China CRO, installed Berkeley Lights' Beacon® Optofluidic platform to offer B Cell antibody discovery services;

Company News

• WuXi Biologics, a China biologics CRO/CMO, began building a large manufacturing center for innovative biologics in Chengdu;

Trials and Approvals

• Suzhou's Innovent and its partner Lilly announced their anti-CD20 biosimilar to Rituxan met its primary endpoints in two China clinical trials.

Stock Symbols: (NSDQ: BCAC) (NSDQ: CPIX) (NSDQ: MASI) (SHZ: 300760) (NSDQ: ONTX) (HK: 2269) (HK: 01801) (NYSE: LLY)

Share this with colleagues:

     
 

Hangzhou's AnHeart Completes $14.6 Million A Funding from Decheng

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

AnHeart Therapeutics of Hangzhou raised $14.6 million in a Series A round from Decheng Capital, a China life science investor. AnHeart uses its expertise in global clinical development to develop innovative products, which it partners at near-term value inflection points. In late 2018, AnHeart in-licensed global rights to an oral, highly selective ROS1/NTRK small molecule inhibitor from Daiichi Sankyo. AB-106 is in two Phase I clinical trials in the US and Japan. After the Phase I trial, AnHeart will assume responsibility for further clinical development. More details....

Share this with colleagues:

     
 

ChemPartner Adds B Cell Discovery from Berkeley Lights to Offerings

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Shanghai ChemPartner, a China CRO, extended its collaboration with Berkeley Lights Inc. of South San Francisco by installing BLI's Beacon® Optofluidic platform to offer B Cell antibody discovery services to its clients. ChemPartner will combine BLI's antibody discovery workflow for B cells with ChemPartner's assays. The Beacon® platform can screen tens of thousands of plasma B cells or gene-edited cells automatically, speeding up a usually time-consuming process. The Beacon® platform enables plasma B cell characterization in less than a day. More details....

Share this with colleagues:

     
 

Leads Biolabs Grants License for Inhaled Delivery of its Immunotherapies

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Leads Biolabs of Maryland, a fully-owned subsidiary of a US-China JV, Nanjing Leads Biolabs, granted Pneuma Respiratory an exclusive license to develop Leads' panel of immuno-oncology mAbs and fusion protein molecules for pulmonary delivery. Pneuma, based in North Carolina, has developed a proprietary breath-activated digital inhaler. Using the inhaler, Pneuma will develop Leads' immuno-oncology therapies for pulmonary delivery to treat oncologic or immune-mediated lung diseases. Leads has developed a portfolio of more than ten novel mono or bispecific antibodies for cancer immunotherapy and other major diseases. More details....

Share this with colleagues:

     
 

WuXi Biologics Starts Building Chengdu Manufacturing Plant, its 12th Globally

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

WuXi Biologics, a China biologics CRO/CMO, has begun construction of a new 1.3 million square foot integrated manufacturing center for innovative biologics in Chengdu, one of the largest cities in Southwest China. The facility will be WuXi Biologics' 12th drug substance manufacturing facility. Bu 2022, WuXi plans to have a total production capacity of 220,000 liters, with facilities around the world, including China, Ireland, Singapore and US. Initially, the Changdu facility will have a bioreactor capacity of 48,000 liters. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:

     
 

More Recent Articles

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.


 Not a ChinaBio®Today Subscriber?

Here's what you get with a paid subscription to ChinaBio® Today:
  • Website access to all current articles and commentary
  • Full access to over 2000 archived articles on the biotech industry

Greg B. Scott
Executive Editor
ChinaBio® Today


ChinaBio and ChinaBio Today are trademarks of ChinaBio LLC


 


Safely Unsubscribe ArchivesPreferencesContactSubscribePrivacy